{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:36:53Z","timestamp":1793957813002,"version":"4.8.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.humpath.2024.105700","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T03:48:04Z","timestamp":1732592884000},"page":"105700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["High-grade B-cell lymphomas: Double hit and non-double hit"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-4587","authenticated-orcid":false,"given":"Lianqun","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-0523","authenticated-orcid":false,"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.humpath.2024.105700_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.humpath.2024.105700_bib2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world Health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.humpath.2024.105700_bib3","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international Consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.humpath.2024.105700_bib4","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41379-018-0067-x","article-title":"MYC\/BCL2\/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC\/BCL2 and MYC\/BCL6 double hit lymphomas","volume":"31","author":"Huang","year":"2018","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.humpath.2024.105700_bib5","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3324\/haematol.2021.279631","article-title":"Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and\/or BCL6 rearrangements characterized by whole-exome sequencing","volume":"107","author":"Kunstner","year":"2022","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.humpath.2024.105700_bib6","first-page":"2493","article-title":"Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population","volume":"141","author":"Alduaij","year":"2023","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.humpath.2024.105700_bib7","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg lymphoma biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.humpath.2024.105700_bib8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/17474086.2018.1494567","article-title":"Advances in pathological understanding of high-grade B cell lymphomas","volume":"11","author":"Li","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/COC.0000000000000427","article-title":"Challenges and opportunities for high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangement (Double-hit lymphoma)","volume":"42","author":"Zeng","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2024.105700_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pathol.2019.09.008","article-title":"High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification","volume":"52","author":"Ok","year":"2020","journal-title":"Pathology"},{"issue":"1","key":"10.1016\/j.humpath.2024.105700_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","article-title":"B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2024.105700_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PAP.0b013e3182a289f2","article-title":"MYC\/BCL2 double-hit high-grade B-Cell lymphoma","volume":"20","author":"Li","year":"2013","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"10.1016\/j.humpath.2024.105700_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41375-022-01778-9","article-title":"High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL\/HGBL-DH than DLBCL","volume":"37","author":"Li","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.humpath.2024.105700_bib14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2024024251","article-title":"Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)","volume":"144","author":"Hilton","year":"2024","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.humpath.2024.105700_bib15","doi-asserted-by":"crossref","first-page":"38122","DOI":"10.18632\/oncotarget.9473","article-title":"Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC\/BCL2 double hit lymphoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.humpath.2024.105700_bib16","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.humpath.2024.105700_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41379-018-0112-9","article-title":"High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma","volume":"32","author":"Ok","year":"2019","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.humpath.2024.105700_bib18","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/PAS.0000000000000818","article-title":"Further exploration of the complexities of large B-cell lymphomas with MYC abnormalities and the importance of a blastoid morphology","volume":"41","author":"Moore","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41379-021-00909-4","article-title":"Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge","volume":"35","author":"Khanlari","year":"2022","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.humpath.2024.105700_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100349","article-title":"The clinicopathologic features and molecular signatures of blastoid high-grade B cell lymphoma, not otherwise specified","volume":"36","author":"Qiu","year":"2023","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030848","article-title":"Blastoid B-cell neoplasms: diagnostic challenges and solutions","volume":"15","author":"Qiu","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.humpath.2024.105700_bib22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1309\/AJCP7YLDTJPLCE5F","article-title":"\"Double-Hit\" mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression","volume":"134","author":"Wu","year":"2010","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2024.105700_bib23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1309\/AJCPL11MAHISIJBQ","article-title":"The unique immunophenotype of double-hit lymphomas","volume":"135","author":"Harrington","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2024.105700_bib24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/cyto.b.21770","article-title":"Bright CD38 expression by flow cytometric analysis is a biomarker for double\/triple hit lymphomas with a moderate sensitivity and high specificity","volume":"96","author":"Alsuwaidan","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"issue":"11","key":"10.1016\/j.humpath.2024.105700_bib25","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.humpath.2024.105700_bib26","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.humpath.2014.06.005","article-title":"BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma","volume":"45","author":"Kendrick","year":"2014","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2024.105700_bib27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/PAS.0b013e318244e2ba","article-title":"High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma","volume":"36","author":"Green","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"28","key":"10.1016\/j.humpath.2024.105700_bib28","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.humpath.2024.105700_bib29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/PAS.0000000000000542","article-title":"High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high P53 expression and a poor prognosis","volume":"40","author":"Li","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/his.14585","article-title":"EBV(+) high-grade B cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements: a multi-institutional study","volume":"80","author":"Liu","year":"2022","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.humpath.2024.105700_bib31","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.3324\/haematol.2018.207290","article-title":"False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms","volume":"104","author":"King","year":"2019","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.humpath.2024.105700_bib32","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/bloodadvances.2018023572","article-title":"High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology","volume":"2","author":"Chong","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.leu.2404529","article-title":"Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas","volume":"21","author":"Bertrand","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.humpath.2024.105700_bib34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/1947601910377488","article-title":"Targeting MYC-regulated miRNAs to combat cancer","volume":"1","author":"Frenzel","year":"2010","journal-title":"Genes Cancer"},{"issue":"4","key":"10.1016\/j.humpath.2024.105700_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bcmd.2010.08.002","article-title":"The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma","volume":"45","author":"Smith","year":"2010","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"10.1016\/j.humpath.2024.105700_bib36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2010.08159.x","article-title":"Advances in the understanding of MYC-induced lymphomagenesis","volume":"149","author":"Klapproth","year":"2010","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.humpath.2024.105700_bib37","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/leu.2015.34","article-title":"The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum","volume":"29","author":"Momose","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.humpath.2024.105700_bib38","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.3324\/haematol.2018.198572","article-title":"Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements","volume":"104","author":"Evrard","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.humpath.2024.105700_bib39","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41375-019-0691-6","article-title":"Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC\/BCL2 double-hit","volume":"34","author":"Cucco","year":"2020","journal-title":"Leukemia"},{"issue":"7337","key":"10.1016\/j.humpath.2024.105700_bib40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.humpath.2024.105700_bib41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.humpath.2024.105700_bib42","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib43","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib44","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-Cell-Like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.humpath.2024.105700_bib45","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1182\/bloodadvances.2023010673","article-title":"Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL","volume":"7","author":"Davies","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.humpath.2024.105700_bib46","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood.2019002600","article-title":"The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH","volume":"134","author":"Hilton","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.humpath.2024.105700_bib47","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2024024251","article-title":"Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)","volume":"144","author":"Hilton","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.humpath.2024.105700_bib48","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.humpath.2024.105700_bib49","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.humpath.2024.105700_bib50","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jtct.2023.05.011","article-title":"Survival outcomes for patients with relapsed\/refractory aggressive B cell lymphomas following receipt of high-dose chemotherapy\/autologous stem transplantation and\/or chimeric antigen receptor-modified T cells","volume":"29","author":"Landsburg","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.humpath.2024.105700_bib51","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/modpathol.2016.178","article-title":"P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC\/BCL2 expression in diffuse large B-cell lymphoma","volume":"30","author":"Wang","year":"2017","journal-title":"Mod Pathol"},{"issue":"22","key":"10.1016\/j.humpath.2024.105700_bib52","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.humpath.2024.105700_bib53","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3324\/haematol.2013.091827","article-title":"Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma","volume":"99","author":"Aukema","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.humpath.2024.105700_bib54","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.29781","article-title":"Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma","volume":"122","author":"Landsburg","year":"2016","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.humpath.2024.105700_bib55","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/his.12884","article-title":"MYC\/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis","volume":"68","author":"Li","year":"2016","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib57","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1309\/AJCPBWVHTF7RRSA4","article-title":"Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics","volume":"142","author":"Turakhia","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"3 Supplement","key":"10.1016\/j.humpath.2024.105700_bib58","article-title":"MYC and BCL6 double hit lymphoma (DHL): a clinicopathologic study of 60 cases in comparison to BCL2-DHL and diffuse large B-cell lymphoma (DLBCL)","volume":"103","author":"Kim","year":"2023","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.humpath.2024.105700_bib59","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.2024024048","article-title":"Testing for t(3;8) in MYC\/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival","volume":"144","author":"Maybury","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib60","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41375-023-02134-1","article-title":"Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential","volume":"38","author":"Zhang","year":"2024","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.humpath.2024.105700_bib61","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.humpath.2024.105700_bib62","first-page":"3","article-title":"Characterization of the genetic landscape of high-grade B-cell lymphoma, NOS\u2013 an LLMPP project","volume":"39","author":"Collinge","year":"2021","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2024.105700_bib63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00428-022-03404-6","article-title":"Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma","volume":"482","author":"King","year":"2023","journal-title":"Virchows Arch"},{"issue":"21","key":"10.1016\/j.humpath.2024.105700_bib64","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1182\/bloodadvances.2023009731","article-title":"High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study","volume":"7","author":"Zayac","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2024.105700_bib65","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.2147\/CMAR.S243753","article-title":"High-grade B-cell lymphomas, not otherwise specified: a study of 41 cases","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.humpath.2024.105700_bib66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12288-021-01427-8","article-title":"Comparison between CHOP and DAEPOCH with or without rituximab in adult high grade B cell lymphoma, not otherwise specified; A retrospective study from a tertiary cancer hospital in South India","volume":"38","author":"Moharana","year":"2022","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.humpath.2024.105700_bib67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.humpath.2021.04.014","article-title":"Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma","volume":"114","author":"Chaudhary","year":"2021","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.humpath.2024.105700_bib68","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/modpathol.2017.134","article-title":"Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements","volume":"31","author":"Miyaoka","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2024.105700_bib69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.humpath.2016.07.025","article-title":"Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature","volume":"58","author":"Miao","year":"2016","journal-title":"Hum Pathol"},{"issue":"8","key":"10.1016\/j.humpath.2024.105700_bib70","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3109\/08880018.2015.1087611","article-title":"De novo MYC and BCL2 double-hit B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in pediatric and young adult patients associated with poor prognosis","volume":"32","author":"Liu","year":"2015","journal-title":"Pediatr Hematol Oncol"},{"issue":"5","key":"10.1016\/j.humpath.2024.105700_bib71","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3324\/haematol.2019.243071","article-title":"MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma","volume":"106","author":"Wang","year":"2021","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.humpath.2024.105700_bib72","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1182\/blood-2017-02-770503","article-title":"Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.humpath.2024.105700_bib73","first-page":"2196","article-title":"The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC","volume":"137","author":"Collinge","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.humpath.2024.105700_bib74","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/modpathol.2014.95","article-title":"B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC\/BCL2 double-hit lymphomas","volume":"28","author":"Li","year":"2015","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2024.105700_bib75","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjh.14282","article-title":"Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable","volume":"175","author":"Landsburg","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.humpath.2024.105700_bib76","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/modpathol.2017.93","article-title":"Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma","volume":"30","author":"Quesada","year":"2017","journal-title":"Mod Pathol"},{"issue":"28","key":"10.1016\/j.humpath.2024.105700_bib77","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, Doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105700_bib78","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.humpath.2024.105700_bib79","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/ejh.13384","article-title":"MYC rearrangement and MYC\/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma","volume":"104","author":"Xu","year":"2020","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.humpath.2024.105700_bib80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/10428194.2014.907896","article-title":"TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations","volume":"56","author":"Gebauer","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.humpath.2024.105700_bib81","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib82","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ccr.2012.07.014","article-title":"Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma","volume":"22","author":"Monti","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.humpath.2024.105700_bib83","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/10428194.2014.907896","article-title":"TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations","volume":"56","author":"Gebauer","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.humpath.2024.105700_bib84","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1309\/AJCPPHMZ6VHF0WQV","article-title":"p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study","volume":"141","author":"Xie","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib85","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cjp2.10","article-title":"The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit","volume":"1","author":"Clipson","year":"2015","journal-title":"J Pathol Clin Res"},{"issue":"6","key":"10.1016\/j.humpath.2024.105700_bib86","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1158\/1078-0432.CCR-20-2378","article-title":"Double-hit signature with TP53 abnormalities predicts poor survival in patients with germinal center type diffuse large B-cell lymphoma treated with R-CHOP","volume":"27","author":"Song","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.humpath.2024.105700_bib87","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/PAS.0000000000000433","article-title":"MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC\/BCL2 protein double-positive diffuse large B-cell lymphoma","volume":"39","author":"Wang","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib88","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/PAS.0000000000001613","article-title":"A diagnostic approach to the identification of Burkitt-like lymphoma with 11q aberration in aggressive B-cell lymphomas","volume":"45","author":"Horn","year":"2021","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.humpath.2024.105700_bib89","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3324\/haematol.2018.207928","article-title":"Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma","volume":"104","author":"Gonzalez-Farre","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib90","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00428-023-03590-x","article-title":"Emerging entities: high-grade\/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP\/SH lymphoma workshop","volume":"483","author":"Quintanilla-Martinez","year":"2023","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.humpath.2024.105700_bib91","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3960\/jslrt.23007","article-title":"High-grade B-cell lymphoma with 11q aberrations: a single-center study","volume":"63","author":"Yamada","year":"2023","journal-title":"J Clin Exp Hematop"},{"issue":"3","key":"10.1016\/j.humpath.2024.105700_bib92","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3324\/haematol.2022.281646","article-title":"Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B-acute lymphoblastic leukemia\/lymphoma","volume":"108","author":"Qiu","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.humpath.2024.105700_bib93","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/PAS.0000000000001750","article-title":"Mutational landscape of TdT+ large B-cell lymphomas supports their distinction from B-lymphoblastic neoplasms: a multiparameter study of a rare and aggressive entity","volume":"46","author":"Bhavsar","year":"2022","journal-title":"Am J Surg Pathol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724002090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724002090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T16:41:47Z","timestamp":1741279307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817724002090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":93,"alternative-id":["S0046817724002090"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2024.105700","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-grade B-cell lymphomas: Double hit and non-double hit","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2024.105700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105700"}}